INSM Insmed (INSM) Q1 FY26 earnings call
Insmed reported a strong Q1 FY26, driven by BRINSUPRI's exceptional launch performance, which exceeded expectations with robust sequential growth and favorable patient metrics. The company is also advancing its pipeline, with ARIKAYCE showing significant potential for label expansion and TPIP progressing through multiple Phase III trials. Despite international market uncertainties due to MFN, Insmed is well-resourced and aims for cash flow positivity in 2027, focusing on maximizing current product impact and strategic pipeline development.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
INSM operating KPIs by quarter
| KPI | This call Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Patients BRINSUPRI New Starts | ~7,800Similarly, in Q1, we estimate that about 1,500 of the roughly 7,800 new patients who started treatment in the quarter were part of this ready and waiting patient group.Source: earnings call transcript | ~7,000BRINSUPRI added approximately 7,000 new patients in the second quarter, exceeding our previous expectation of approximately 6,300 new patient starts.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.